SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2002; 95: 15041510.
  • 2
    Eby NL, Grufferman S, Flannelly CM, Schold SCJr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988; 62: 24612465.
  • 3
    Corn BW, Marcus SM, Topham A, Hauck W, Curran WJJr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer. 1997; 79: 24092413.
  • 4
    Lutz JM, Coleman MP. Trends in primary cerebral lymphoma. Br J Cancer. 1994; 70: 716718.
  • 5
    van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, van der Maazen RW, Coebergh JW; Working Group of Specialists in Neuro-Oncology in the Southern and Eastern Netherlands. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer. 2002; 94: 15481556.
  • 6
    Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J. Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surg Neurol. 2006; 66: 503506.
  • 7
    Hao D, DiFrancesco LM, Brasher PM, et al. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann Oncol. 1999; 10: 6570.
  • 8
    Krogh-Jensen M, D'Amore F, Jensen MK, et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma. 1995; 19: 223233.
  • 9
    Yau YH, O'Sullivan MG, Signorini D, Ironside JW, Whittle IR. Primary lymphoma of central nervous system in immunocompetent patients in south-east Scotland [letter]. Lancet. 1996; 348: 890.
  • 10
    Au WY, Chan AC, Srivastava G, Leung SY, Liang R. Incidence and pathology of primary brain lymphoma in Hong Kong Chinese patients. Leuk Lymphoma. 2000; 37: 175179.
  • 11
    Powari M, Radotra B, Das A, Banerjee AK. A study of primary central nervous system lymphoma in northern India. Surg Neurol. 2002; 57: 113116.
  • 12
    Sarkar C, Sharma MC, Deb P, Singh R, Santosh V, Shankar SK. Primary central nervous system lymphoma—a hospital-based study of incidence and clinicopathological features from India, 1980–2003. J Neurooncol. 2005; 71: 199204.
  • 13
    Haldorsen IS, Aarseth JH, Hollender A, Larsen JL, Espeland A, Mella O. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway. Acta Oncol. 2004; 43: 520529.
  • 14
    Panageas KS, Elkin EB, DeAngelis LM, Ben Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975–1999—A population-based analysis. Cancer. 2005; 104: 24662472.
  • 15
    Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999; 43: 241247.
  • 16
    Shibamoto Y, Ogino H, Hasegawa M, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005; 62: 809813.
  • 17
    Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol. 2000; 11: 927937.
  • 18
    Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005; 19: 611627.
  • 19
    O'Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006; 64: 408413.
  • 20
    Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998; 16: 859863.
  • 21
    Herrlinger U, Schabet M, Brugger W, et al. Primary central nervous system lymphoma 1991–1997: outcome and late adverse effects after combined modality treatment. Cancer. 2001; 91: 130135.
  • 22
    Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998; 16: 864871.
  • 23
    Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol. 1999; 43: 219226.
  • 24
    Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000; 92: 261266.
  • 25
    Remick SC, Diamond C, Migliozzi JA, et al. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature. Medicine (Baltimore). 1990; 69: 345360.
  • 26
    Coulon A, Lafitte F, Hoang-Xuan K, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002; 12: 329340.
  • 27
    Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol. 2001; 176: 13191326.
  • 28
    Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005; 44: 728734.
  • 29
    Shenkier TN, Voss N, Chhanabhai M, et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer. 2005; 103: 10081017.
  • 30
    Jaffe ES, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
  • 31
    Krogh-Jensen M, D'Amore F, Jensen MK, et al. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-baseddata from a Danish lymphoma registry.Danish Lymphoma Study Group, LYFO. Ann Oncol. 1994; 5: 349354.
  • 32
    Goldkuhl C, Ekman T, Wiklund T, Telhaug R. Age-adjusted chemotherapy for primary central-nervous system lymphoma—a pilot study. Acta Oncol. 2002; 41: 2935.
  • 33
    Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K. Trends in incidence of brain and central nervous system tumors in Norway, 1970–1999. Neuroepidemiology. 2004; 23: 101109.
  • 34
    The Cancer Registry of Norway. Cancer in Norway Report, 2003. Oslo, Norway: Cancer Registry of Norway, Institute of Population-Based Cancer Research; 2005.
  • 35
    Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005; 19: 689703.
  • 36
    Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005; 72: 169177.
  • 37
    Harting I, Hartmann M, Jost G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett. 2003; 342: 163166.
  • 38
    Hartmann M, Heiland S, Harting I, et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett. 2003; 338: 119122.
  • 39
    Ferreri AJM, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am. 2005; 19: 629649.
  • 40
    Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21: 266272.
  • 41
    Hayabuchi N, Shibamoto Y, Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys. 1999; 44: 265272.
  • 42
    Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006; 24: 57115715.
  • 43
    Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma [resource online]. Neurosurg Focus. 2006; 21: E12.
  • 44
    Ferreri AJM, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002; 58: 15131520.
  • 45
    Shibamoto Y, Tsuchida E, Seki K, et al. Primary central nervous system lymphoma in Japan 1995–1999: changes from the preceding 10 years. J Cancer Res Clin Oncol. 2004; 130: 351356.
  • 46
    Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998; 41: 615620.
  • 47
    Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by 2 different radiotherapy treatments. J Clin Oncol. 2002; 20: 231236.